Making a case for a $2700-a-month drug

Sibbald, Barbara
November 1999
CMAJ: Canadian Medical Association Journal;11/02/99, Vol. 161 Issue 9, p1173
Academic Journal
Discusses the class of biotherapeutic cancer drugs, trastuzumab (Herceptin), the first monoclonal antibody approved for use in Canada. Ethical questions raised by the cost of the drug; Speculation on the impact to the public health care system and the court system; Testing of the drug in a 4-arm study.


Related Articles

  • Barriers to the uptake of new high-cost cancer drugs.  // PharmacoEconomics & Outcomes News;6/12/2010, Issue 605, p6 

    The article focuses on three studies presented at the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) meeting, which focused on accessibility issues surrounding new high-cost cancer treatments. One examined a hypothetical treatment for HER2-positive breast cancer, which...

  • Bone Loss Due to Cancer Treatment Now Treatable with Prolia.  // Journal of Gerontological Nursing;Nov2011, Vol. 37 Issue 11, p10 

    The article reports on a 2011 decision which the U.S. Food and Drug Administration made to approve the drug denosumab, which is marketed as Prolia. The drug is used to increase bone mass in women at high risk for fracture who are receiving drug therapy for breast cancer and as a treatment to...

  • Novel HER-2 antibody chemotherapy conjugate improves outcomes in breast cancer. Mayor, Susan // British Journal of Hospital Medicine (17508460);Jul2012, Vol. 73 Issue 7, p370 

    The article reports results of a study which revealed that an antibody chemotherapy conjugate has the potential to improve outcomes in women with HER-2 positive metastatic breast cancer.

  • New Hope for Some Breast Cancer Patients.  // Medical Update;Jun99, Vol. 22 Issue 12, p4 

    Presents information on Herceptin, a monoclonal antibody that treats metastatic breast cancer. Mechanism of action; Potential serious risks associated; Most common adverse effects related to Herceptin therapy.

  • Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada. Herring, William; Pearson, Isobel; Purser, Molly; Nakhaipour, Hamid; Haiderali, Amin; Wolowacz, Sorrel; Jayasundara, Kavisha; Nakhaipour, Hamid Reza // PharmacoEconomics;Jan2016, Vol. 34 Issue 1, p77 

    Objective: Our objective was to estimate the cost effectiveness of ofatumumab plus chlorambucil (OChl) versus chlorambucil in patients with chronic lymphocytic leukaemia for whom fludarabine-based therapies are considered inappropriate from the perspective of the publicly funded...

  • NEW HOPE FOR CANCER. Lemonick, Michael D.; Park, Alice; Cray, Dan; Gorman, Christine // Time International (South Pacific Edition);5/28/2001, Issue 21, p48 

    Reports on developments in the treatment of cancer, as of May, 2001. Success of the drug Glivec; Mention of therapies that prevent the chemicals called growth factors from reaching tumors; Use of the body's immune system to seek and destroy cancerous tissue; Monoclonal antibodies, including the...

  • New Lymphoma Therapies Inspired by Functional and Structural Genomics. STAUDT, LOUIS M. // Oncologist;Oct2013 Supplement 1, Vol. 18, pS2 

    Seeking an unbiased method to discover therapeutic targets in cancer, we developed a loss-of-function genetic screen using genomic-scale libraries of small hairpin RNAs that mediate RNA interference. These "Achilles' heel" screens are designed to reveal genes essential for cancer cell...

  • Salvage Therapy in Hodgkin's Lymphoma. MENDLER, JASON H.; FRIEDBERG, JONATHAN W. // Oncologist;Apr2009, Vol. 14 Issue 4, p425 

    Hodgkin's lymphoma (HL) is a commonly cured malignancy. Unfortunately, patients who are refractory to or relapse after first-line treatment pose a significant therapeutic challenge. There is evidence that these patients are best treated with an approach involving salvage chemotherapy followed by...

  • Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan. Lane, Michael A.; Renga, Vijay; Pachner, Andrew R.; Cohen, Jeffrey A. // Case Reports in Neurological Medicine;1/29/2015, Vol. 2015, p1 

    PML caused by John Cunningham (JC) virus is a rare but an increasingly recognized entity. With the advent of newer immunomodulatory therapies with monoclonal antibodies, there is an increasing incidence of PML. Initially concern was restricted to patients treated for multiple sclerosis with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics